Seer (SEER)
Provides the Proteograph platform for deep, unbiased proteomics research.
Something off on this page? Send us feedback.
Sells the Proteograph platform: engineered nanoparticles, automation instruments, consumables, and analytical software for research proteomics. Access comes through instrument and kit purchases or the Seer Technology Access Center. The business is organized around a single platform.
Built around the Proteograph platform, engineered nanoparticles, automation instruments, consumables, and analytical software support deep, unbiased proteomics research. The current suite includes the Proteograph ONE Assay and SP200 Automation Instrument, and is intended for research rather than diagnostic or clinical use. Its workflow is designed to make deep proteomics usable at scale.
Instrument and kit purchases sit alongside access through the Seer Technology Access Center. The products serve researchers seeking molecular insight into biology and disease, while teams span North America, the European Union, and the United Kingdom. The business is organized around a single platform rather than unrelated segments.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Target | Target: — | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $152.9M · Total debt $22.4M · Total assets $256.6M · Shareholders' equity $225.7M
- Revenue
- $3.1M
- Operating income
- −$16.8M
- Net income
- −$16.9M
No dividends on record.
| Institutions | 37.04% | 20.51M shares | |
|---|---|---|---|
| 59 holders · as of Jun 30, 2026 | |||
| Insiders | 20.06% | 11.11M shares | |
| 9 holders · as of Aug 19, 2026 | |||
| Strategic holders | 14.84% | 8.22M shares | |
| 2 holders · as of Feb 7, 2022 | |||
| Other | 28.06% | 15.54M shares | |
| remainder | |||
55.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Omid Farokhzad1,2Insiderdirector, officer: CEO AND CHAIR | 16.32% | 6.92M · 2.12M | filed May 15, 2026 |
SoftBank Group Corp.Institution | 9.27% | 5.14M | as of Jun 30, 2026 |
aMoon Growth Fund Limited Partnership3Strategic10 percent owner | 8.89% | 4.11M · 810,961 | filed Jan 24, 2022 |
The Vanguard GroupInstitution | 7.62% | 4.22M | filed Feb 10, 2022 |
BlackRock, Inc.Strategic | 5.95% | 3.30M | filed Feb 7, 2022 |
- Omid Farokhzad's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.92M) is used instead.
- Omid Farokhzad reports a block also reported by BlackRock, Inc.; it is counted once, under BlackRock, Inc.
- aMoon Growth Fund Limited Partnership's transaction reports restate only vehicles that traded; the 2022 ownership statement (4.11M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,309 | $2.03 |
| Jul 8, 2026 | Dipchand Nishar | director | −10,660 | $2.18 |
| May 20, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,303 | $1.69 |
| Feb 18, 2026 | Omid Farokhzad | director, officer: CEO AND CHAIR | −24,385 | $1.99 |
| Feb 18, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,743 | $1.99 |
- Thermo Fisher Scientific
Orbitrap and Astral workflows for discovery proteomics
- Bruker
timsTOF mass spectrometry and proteomics workflows
- Agilent Technologies
LC/MS, sample-prep, and automation workflows for proteomics
- Danaher
SCIEX mass-spectrometry and separation workflows for proteomics
- Bio-Techne
Protein-analysis reagents and instruments for proteomics research
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Seer | $1.86 | −0.53% | $102.3M | — | — | 7.4 | −23.4% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Bruker | $61.21 | −0.02% | $9.37B | — | 27.0 | 2.7 | +5.2% |
| Agilent Technologies | $166.00 | −0.77% | $45.75B | 31.9 | 25.5 | 6.2 | +8.1% |
| Danaher | $220.87 | −0.11% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Bio-Techne | $72.55 | 0.00% | $11.35B | 62.5 | 35.0 | 9.3 | +1.3% |
| Median | 36.9 | 25.5 | 6.0 | +5.5% |